GB0720886D0 - Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer - Google Patents

Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer

Info

Publication number
GB0720886D0
GB0720886D0 GBGB0720886.1A GB0720886A GB0720886D0 GB 0720886 D0 GB0720886 D0 GB 0720886D0 GB 0720886 A GB0720886 A GB 0720886A GB 0720886 D0 GB0720886 D0 GB 0720886D0
Authority
GB
United Kingdom
Prior art keywords
cancer
treatment
modified release
release compositions
fluorocytidine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB0720886.1A
Other versions
GB2442615A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of GB0720886D0 publication Critical patent/GB0720886D0/en
Publication of GB2442615A publication Critical patent/GB2442615A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0720886A 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer Pending GB2442615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67050705P 2005-04-12 2005-04-12
PCT/US2006/013629 WO2006110800A1 (en) 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer

Publications (2)

Publication Number Publication Date
GB0720886D0 true GB0720886D0 (en) 2007-12-05
GB2442615A GB2442615A (en) 2008-04-09

Family

ID=37087358

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0720886A Pending GB2442615A (en) 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer

Country Status (7)

Country Link
EP (1) EP1874271A4 (en)
JP (1) JP2008535920A (en)
CA (1) CA2604192A1 (en)
DE (1) DE112006000873T5 (en)
ES (1) ES2327195B1 (en)
GB (1) GB2442615A (en)
WO (1) WO2006110800A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
WO2016203358A1 (en) * 2015-06-13 2016-12-22 Intas Pharmaceuticals Ltd. Extended release capecitabine capsules
JP2020514314A (en) * 2017-02-06 2020-05-21 インタス ファーマシューティカルズ リミテッド Compositions containing immediate release and sustained release capecitabine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1998018452A1 (en) * 1996-10-25 1998-05-07 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
DE69939748D1 (en) * 1998-11-02 2008-11-27 Elan Pharma Int Ltd MULTIPARTIC COMPOSITION OF METHYLPHENIDATE WITH MODIFIED RELEASE
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE344670T1 (en) * 2000-02-28 2006-11-15 Pfizer Entpr Sarl SYNERGISTIC COMBINATION FOR THE TREATMENT OF COLORECTAL CARCINOMA
US20020019365A1 (en) * 2000-06-02 2002-02-14 Jones Richard E. Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine

Also Published As

Publication number Publication date
EP1874271A4 (en) 2012-01-25
EP1874271A1 (en) 2008-01-09
WO2006110800A1 (en) 2006-10-19
GB2442615A (en) 2008-04-09
ES2327195A1 (en) 2009-10-26
CA2604192A1 (en) 2006-10-19
JP2008535920A (en) 2008-09-04
DE112006000873T5 (en) 2008-03-06
ES2327195B1 (en) 2010-07-09

Similar Documents

Publication Publication Date Title
IL245513A0 (en) Therapeutic compositions comprising ingenol-3-angelate
IL190882A0 (en) Compositions for cancer therapy
HK1131577A1 (en) Compositions for treating cancer
EP1876186A4 (en) Prophylactic/therapeutic agent for cancer
EP2152722A4 (en) Compositions comprising mir34 therapeutic agents for treating cancer
HK1137158A1 (en) Formulations for cancer treatment
ZA200709287B (en) Therapeutic compositions
EP1996612A4 (en) Compositions for treatment of cancer
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
EP2049151A4 (en) Methods and compositions for the treatment of cancer
IL197235A0 (en) Therapeutic compositions
EP1908459A4 (en) Composition for prevention of cancer
HK1110224A1 (en) Therapeutic agent for cancer
EP1979487A4 (en) Cobalamin compositions for the treatment of cancer
EP1904088A4 (en) Compositions and methods for the treatment of cancer
GB0720887D0 (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
GB0720886D0 (en) Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
EP1923072A4 (en) Prophylactic/therapeutic agent for cancer
EP2073815A4 (en) Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
EP1862180A4 (en) Prophylactic/therapeutic agent for cancer
TWI398260B (en) Medical compositions for inhibiting brain tumor
TWI372626B (en) Medical compositions for inhibiting brain tumor
GB0503566D0 (en) Treatment for cancer